Related Experiment Video

Updated: Jun 6, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Cardiac gene therapy

Antoine H Chaanine1, Jill Kalman, Roger J Hajjar

  • 1Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York 10029, USA.

Seminars in Thoracic and Cardiovascular Surgery
|November 25, 2010
PubMed

Insights

Gene therapy offers a promising future for treating heart failure by targeting malfunctioning cardiomyocytes. Recombinant adeno-associated virus vectors show potential as effective delivery vehicles for these advanced therapies.

Area of Science:

  • Cardiology
  • Molecular Medicine
  • Gene Therapy

Background:

  • Heart failure is a progressive condition with increasing incidence and prevalence, particularly in aging populations.
  • Frequent hospitalizations in heart failure patients are linked to high mortality and morbidity rates.
  • Current understanding of heart failure's molecular pathology and pathophysiology is crucial for developing novel treatments.

Purpose of the Study:

  • To explore gene therapy as a promising approach for treating heart failure.
  • To identify novel therapeutic targets for restoring or attenuating cardiomyocyte damage.
  • To investigate efficient vector and delivery systems for gene therapy in cardiac applications.

Main Methods:

  • Focus on understanding the molecular pathology and pathophysiology of heart failure.
  • Exploration of gene therapy strategies for cardiomyocyte repair.
  • Evaluation of recombinant adeno-associated virus (AAV) vectors for cardiac gene delivery.

Main Results:

  • Gene therapy presents a promising avenue for heart failure treatment.
  • Recombinant adeno-associated virus vectors demonstrate potential as therapeutic delivery vehicles.
  • Efficient transduction, long-term expression, and immune response evasion are key considerations for vector development.

Conclusions:

  • Advancements in understanding heart failure pathogenesis can lead to innovative gene therapies.
  • Recombinant adeno-associated virus vectors are a promising platform for molecular medicine in treating heart failure.
  • Developing effective vectors and delivery methods is critical for successful cardiac gene therapy.

More Related Videos

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice06:42

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice

Published on: April 16, 2018

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...